Literature DB >> 18456078

Cesarean section and the outcome of very preterm and very low-birthweight infants.

Michael H Malloy1, Snehal Doshi.   

Abstract

Births of extremely preterm infants, less than 26 weeks' gestation, by cesarean section have increased significantly in the United States over the past decade. The justification for this increase is not well supported in the literature. This review examines recent analyses that suggest there may be some survival advantage for infants less than 26 weeks delivered by cesarean section. The appropriateness of intervening with cesarean sections for these very immature infants, however, remains uncertain.

Entities:  

Mesh:

Year:  2008        PMID: 18456078     DOI: 10.1016/j.clp.2008.03.008

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  4 in total

1.  No relationship between mode of delivery and neonatal mortality and neurodevelopment in very low birth weight infants aged two years.

Authors:  Jia-Jun Zhu; Ying-Ying Bao; Guo-Lian Zhang; Li-Xin Ma; Ming-Yuan Wu
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

2.  Trends in Overall Mortality, and Timing and Cause of Death among Extremely Preterm Infants near the Limit of Viability.

Authors:  Jae Hyun Park; Yun Sil Chang; Sein Sung; So Yoon Ahn; Won Soon Park
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

3.  Improved Survival of Periviable Infants after Alteration of the Threshold of Viability by the Neonatal Resuscitation Program 2015.

Authors:  Yen-Ju Chen; Wen-Hao Yu; Li-Wen Chen; Chao-Ching Huang; Lin Kang; Hui-Shan Lin; Osuke Iwata; Shin Kato; Mohamed Hamed Hussein; Yung-Chieh Lin
Journal:  Children (Basel)       Date:  2021-01-04

4.  Cesarean section was not associated with mortality or morbidities advantage in very low birth weight infants: a nationwide cohort study.

Authors:  Jin Kyu Kim; Yun Sil Chang; Jong Hee Hwang; Myung Hee Lee; Won Soon Park
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.